Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228947 | 0.86 | CA1 (0.54) | — | |
| SCHEMBL30468424 | 0.86 | CA1 (0.54) | — | |
| SCHEMBL10700966 | 0.83 | NPC1 (0.55) | HDAC8HDAC6 | |
| SCHEMBL28381607 | 0.80 | MRGPRX4 (0.46) | — | |
| SCHEMBL2848161 | 0.79 | MAOB (0.60) | LTB4RLTB4R2MAOBPTGESNR4A2 | |
| SCHEMBL21465770 | 0.78 | BCHE (0.70) | MAOBBCHE | |
| SCHEMBL21981026 | 0.78 | NR4A2 (0.57) | LTB4RLTB4R2MAOBNR4A2SMPD1 | |
| SCHEMBL10960772 | 0.77 | HPGD (0.63) | NR4A2LTA4HBCHECYP4F2CYP4A11 | |
| SCHEMBL20211905 | 0.77 | EPHX2 (0.61) | LTB4RLTB4R2NR4A2SMPD1LTA4H | |
| SCHEMBL670027 | 0.76 | MAOB (0.68) | LTB4RLTB4R2MAOBNR4A2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100441188-C | Benzazepine * derivatives as MAO-B inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| EP-1680127-B1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070117791-A1 | Bicyclic compounds | JOLIDON SYNESE | 2007-05-24 | — | — | US | disclosed |
| US-7173023-B2 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| CN-1871013-A | Benzazepine derivatives as MAO-B inhibitors | HOFFMANN LA ROCHE (CH) | 2006-11-29 | — | — | CN | disclosed |
| EP-1680127-A1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| US-20050107360-A1 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005039591-A1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107360-A1 | Bicyclic compounds | MAOB, MAOA, XDH | LTB4R 864/4885LTB4R2 730/4885MAOB 1/4885 |
| US-20070117791-A1 | Bicyclic compounds | MAOB, MAOA, XDH | LTB4R 743/4885LTB4R2 598/4885MAOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.